ESTRO 35 2016 _____________________________________________________________________________________________________ mg/m2 (IRMA 1, 2, 3, 5) or Cetuximab 400 mg/m2 (IRMA 4). A dose of 67.5 Gy in 30 fractions (IRMA 1, 2, and 4) or 70.5 Gy in 30 fractions (IRMA 3, 4, and 5) was delivered to primary tumor and involved nodes, 60 Gy were delivered to high risk and 55.5 Gy to low risk lymph node areas. Static (IMRT) or volumetric (VMAT) intensity modulated technique with simultaneous integrated boost was used.
Material and Methods:
Fifty patients, who underwent adaptive IMRT for nasopharyngeal and oropharyngeal cancers, were included in the present study. Eighty-four percent of patients (42/50) received concurrent radio-chemotherapy and 92% (44/50) were in locally advanced stage. Dose-volume parameters related to constrictor muscles (superior constrictor muscle, SCM; middle constrictor muscle, MCM; inferior constrictor muscle, ICM and whole pharyngeal constrictor muscle, CM), and parotid glands were analyzed using dose-volume histograms (DVHs). All patients underwent replanning CT scan after 5 weeks of radiation therapy and the target and OARs were re-contoured on fusion images after co-registration. The volumetric variations of pharyngeal constrictor muscles and parotid glands were measured. Volumetric variations and dose-volume parameters were associated to acute and late dysphagia and xerostomia according to RTOG score, quality of life questionnaires (PSS-H&N e QLQ-H&N35), and oesophageal transit .
Results: Volumetric variations and dose-volume parameters of pharyngeal constrictor muscles and parotid glands are reported in Table 1 . Adaptive IMRT achieved a good sparing of parotid glands (mean dose 24.9 Gy) and constrictor muscles (mean dose 51.2 Gy). Acute dysphagia, was scored as grade 0-1 in 18/50 patients (36%) and as grade 2-3 in 32/50 (64%). Acute xerostomia, was scored as grade 0-1 in 21/50 patients (42%) and as grade 2-3 in 29/50 (58%). Volumetric variations and dose-volume parameters of the constrictor muscles and parotid glands did not correlate with acute toxicity (p>0.05). At 2 years median follow-up (range 6-67 months), late dysphagia was scored as grade 0-1 in 40/50 of patients (80%) and as grade 2-3 in 10/50 (20%). Late xerostomia was scored as grade 0-1 in 42/50 of patients (84%) and as grade 2-3 in 8/50 (16%). The analysis of the correlation of volumetric variations and dose-volume parameters with clinical data (RTOG score for late toxicity, quality of life questionnaires and oesophageal transit) is ongoing.
Conclusion:
During radiotherapy, pharyngeal constrictor muscles and salivary glands underwent volumetric variations. Volumetric variations and dosimetric findings did not correlate with acute toxicity, probably because of the complexity and multifactorial pathogenesis of acute dysphagia and xerostomia. The ongoing analysis on the correlation of late toxicity data with volumetric variations and dose-volume parameters may help in the optimization of IMRT treatment planning.
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